1. Home
  2. ABR vs SNDX Comparison

ABR vs SNDX Comparison

Compare ABR & SNDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Arbor Realty Trust

ABR

Arbor Realty Trust

HOLD

Current Price

$5.12

Market Cap

1.5B

Sector

Real Estate

ML Signal

HOLD

Logo Syndax Pharmaceuticals Inc.

SNDX

Syndax Pharmaceuticals Inc.

HOLD

Current Price

$22.62

Market Cap

1.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ABR
SNDX
Founded
2003
2005
Country
United States
United States
Employees
653
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.5B
1.6B
IPO Year
N/A
2014

Fundamental Metrics

Financial Performance
Metric
ABR
SNDX
Price
$5.12
$22.62
Analyst Decision
Hold
Strong Buy
Analyst Count
5
13
Target Price
$9.90
$38.69
AVG Volume (30 Days)
3.9M
2.3M
Earning Date
05-08-2026
04-30-2026
Dividend Yield
15.42%
N/A
EPS Growth
N/A
11.56
EPS
N/A
N/A
Revenue
N/A
$172,352,000.00
Revenue This Year
N/A
$107.19
Revenue Next Year
N/A
$41.88
P/E Ratio
$9.29
N/A
Revenue Growth
N/A
627.84
52 Week Low
$4.86
$9.42
52 Week High
$12.58
$25.59

Technical Indicators

Market Signals
Indicator
ABR
SNDX
Relative Strength Index (RSI) 44.89 53.99
Support Level $4.99 $22.40
Resistance Level $5.49 $25.38
Average True Range (ATR) 0.19 1.30
MACD 0.04 -0.13
Stochastic Oscillator 37.90 38.55

Price Performance

Historical Comparison
ABR
SNDX

About ABR Arbor Realty Trust

Arbor Realty Trust Inc is a specialized real estate finance company. It invests in a diversified portfolio of structured finance assets in the multifamily, SFR, and commercial real estate markets, consisting of bridge and mezzanine loans, including junior participating interests in first mortgages, preferred, and direct equity. In addition, it may also directly acquire real property and invest in real estate-related notes and certain mortgage-related securities. The company has two business segments, Structured Business and Agency Business. It generates a majority of its revenue from the Structured Business Segment.

About SNDX Syndax Pharmaceuticals Inc.

Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.

Share on Social Networks: